rs769765227
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_000434.4(NEU1):c.679G>A(p.Gly227Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000149 in 1,614,046 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.000013 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000015 ( 0 hom. )
Consequence
NEU1
NM_000434.4 missense
NM_000434.4 missense
Scores
11
6
1
Clinical Significance
Conservation
PhyloP100: 7.20
Genes affected
NEU1 (HGNC:7758): (neuraminidase 1) The protein encoded by this gene is a lysosomal enzyme that cleaves terminal sialic acid residues from substrates such as glycoproteins and glycolipids. In the lysosome, this enzyme is part of a heterotrimeric complex together with beta-galactosidase and cathepsin A (the latter is also referred to as 'protective protein'). Mutations in this gene can lead to sialidosis, a lysosomal storage disease that can be type 1 (cherry red spot-myoclonus syndrome or normosomatic type), which is late-onset, or type 2 (the dysmorphic type), which occurs at an earlier age with increased severity. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.98
PP5
Variant 6-31860558-C-T is Pathogenic according to our data. Variant chr6-31860558-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 430342.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr6-31860558-C-T is described in UniProt as null. Variant chr6-31860558-C-T is described in UniProt as null. Variant chr6-31860558-C-T is described in UniProt as null. Variant chr6-31860558-C-T is described in UniProt as null. Variant chr6-31860558-C-T is described in UniProt as null. Variant chr6-31860558-C-T is described in UniProt as null. Variant chr6-31860558-C-T is described in UniProt as null. Variant chr6-31860558-C-T is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NEU1 | NM_000434.4 | c.679G>A | p.Gly227Arg | missense_variant | 4/6 | ENST00000375631.5 | NP_000425.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NEU1 | ENST00000375631.5 | c.679G>A | p.Gly227Arg | missense_variant | 4/6 | 1 | NM_000434.4 | ENSP00000364782.4 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152098Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
2
AN:
152098
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000199 AC: 5AN: 251274Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135844
GnomAD3 exomes
AF:
AC:
5
AN:
251274
Hom.:
AF XY:
AC XY:
3
AN XY:
135844
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000150 AC: 22AN: 1461830Hom.: 0 Cov.: 31 AF XY: 0.0000179 AC XY: 13AN XY: 727208
GnomAD4 exome
AF:
AC:
22
AN:
1461830
Hom.:
Cov.:
31
AF XY:
AC XY:
13
AN XY:
727208
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152216Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74406
GnomAD4 genome
AF:
AC:
2
AN:
152216
Hom.:
Cov.:
32
AF XY:
AC XY:
0
AN XY:
74406
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
1
ALSPAC
AF:
AC:
0
ExAC
AF:
AC:
5
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 17, 2024 | Published functional studies found this variant is associated with significantly reduced enzyme activity (PMID: 11063730, 10767332); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 31956508, 10767332, 24808020, 26141460, 25401298, 19568825, 30023283, 11063730, 33144682, 31711734, 33121223, 32472645, 37530313, 36009508, SeolB2021[Article]) - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 22, 2022 | This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 227 of the NEU1 protein (p.Gly227Arg). This variant is present in population databases (rs769765227, gnomAD 0.004%). This missense change has been observed in individual(s) with sialidosis (PMID: 19568825, 24808020, 26141460). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 430342). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C15"). Experimental studies have shown that this missense change affects NEU1 function (PMID: 10767332). For these reasons, this variant has been classified as Pathogenic. - |
Likely pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC) | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Feb 01, 2021 | - - |
Sialidosis type 2 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Kasturba Medical College, Manipal, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Foundation for Research in Genetics and Endocrinology, FRIGE's Institute of Human Genetics | Sep 16, 2023 | A homozygous missense variant in exon 4 of the NEU1 gene that results in the amino acid substitution of Arginine for Glycine at codon 227 was detected. This variant has not been reported in 1000 genomes and has a MAF of 0.00132%, 0.00199% and 0.00113% in the gnomAD v3.1, gnomAD v2, and topmed databases respectively. This variant has previously been reported in patients affected with sialidosis and associated with significantly reduced enzymatic activity (PMID-10767332). The in-silico prediction is damaging by SIFT, LRT, MutationTaster2. In summary, the variant meets our criteria to be classified as pathogenic. - |
Sialidosis Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 21, 2016 | Variant summary: The NEU1 c.679G>A variant affects a conserved nucleotide, resulting in amino acid change from Gly to Arg. 4/4 in-silico tools predict damaging outcome for this variant (SNPs&GO not captured due to low reliability index). Functional studies show that G227R has a sialidase activity of <10% of normal, and lacks normal processing and lysosomal targeting (Lukong_Hum. Mol. Genet._2000). This variant was found in 5/120902 control chromosomes at a frequency of 0.0000414, which does not significantly exceed maximal expected frequency of a pathogenic NEU1 allele (0.001118). The variant has been identified in homozygous state in patients with Sialidosis type II and in compound heterozygous state in patients with progressive myoclonus epilepsies or late-onset action myoclonus. Taken together, this variant was classified as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Pathogenic
D
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D
MetaSVM
Uncertain
D
MutationAssessor
Uncertain
M
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D
REVEL
Pathogenic
Sift
Uncertain
D
Sift4G
Uncertain
D
Polyphen
D
Vest4
MutPred
Loss of catalytic residue at V228 (P = 0.0423);
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at